Streetbeat News

Revenues

YOU

Analyst ratings for Clear Secure (NYSE:YOU) show a mix of bullish to bearish sentiments, with a recent shift towards more bullish ratings. The average 12-month price target has increased to $37.43, indicating a positive outlook. Clear Secure's financial performance includes a notable revenue growth of 33.3%, a net margin of 8.17%, and strong ROE and ROA figures, suggesting a healthy financial state despite a market capitalization below industry averages.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 1:00 pm

TSLA

Tesla, Inc. (NASDAQ:TSLA) shares fell over 3% in premarket trading due to rumors of production cuts at its Giga Shanghai facility, specifically for Model Y and Model 3 EVs. The company reportedly shifted from a 6.5-day workweek to a five-day schedule, raising concerns about slowing demand in China, a key market. Tesla's insurance registrations in China dropped 6.8% week-over-week, and its wholesale sales in the first two months of 2024 declined by 8% year-over-year. This news comes as Tesla is about to announce its first-quarter sales, with analysts fearing the company might barely surpass its first-quarter delivery figure from the previous year.

Portfolio Pulse from Shanthi Rexaline

March 22, 2024 | 12:04 pm

FLNC

Fluence Energy (NASDAQ:FLNC) has been evaluated by 6 analysts over the last three months, showing a mix of bullish and somewhat bullish sentiments. The average 12-month price target is now $26.67, down 5.43% from the previous $28.20. Analyst actions include maintaining, raising, and lowering ratings and price targets. Fluence Energy is noted for its energy storage products and services, with a positive revenue trend but challenges in ROE and ROA compared to industry standards.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 12:01 pm

VIRT

Analyst ratings for Virtu Financial (NASDAQ:VIRT) show mixed sentiments with a recent negative shift in price target expectations. Four analysts have provided their evaluations, with a mix of bullish and bearish perspectives. The average 12-month price target is now $19.75, down 4.45% from previous estimates. Analysts from Piper Sandler, Morgan Stanley, UBS, and Citigroup have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Virtu Financial's financial indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management are also discussed, highlighting the company's position relative to industry averages.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 12:01 pm

PNR

Pentair (NYSE:PNR) has received mixed analyst ratings over the last three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for PNR has been raised to $86.71, indicating an 8.12% increase from the previous target. Analyst actions include a mix of maintaining, raising, and lowering ratings, reflecting diverse perspectives on Pentair's market position. Despite facing revenue challenges and a high debt-to-equity ratio, Pentair's profitability metrics like net margin, ROE, and ROA outperform industry averages.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 12:00 pm

FTRE

Fortrea Holdings (NASDAQ:FTRE) has been analyzed by 5 analysts, showing a mix of ratings from bullish to bearish. The average 12-month price target is $38.2, reflecting a 14.03% increase from the previous target of $33.50. Analyst actions include ratings from 'Neutral' to 'Buy' with price targets ranging from $33.00 to $44.00. Fortrea, a contract research organization, has shown revenue growth and efficient cost management but faces challenges in ROE, ROA, and high debt levels.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 12:00 pm

HUM

Analyst evaluations for Humana (NYSE:HUM) over the past three months show a mix of bullish and bearish perspectives, with a notable decline in the average 12-month price target to $455.6, a 16.72% decrease. Recent actions by analysts include lowering price targets and maintaining ratings, reflecting adjustments to market conditions and company performance. Humana, a major private health insurer in the U.S., has shown solid revenue growth of 17.93% as of December 31, 2023, but faces challenges with a net margin of -2.04% and a high debt-to-equity ratio of 0.74.

Portfolio Pulse from Benzinga Insights

March 22, 2024 | 12:00 pm

ALOT

AstroNova projects mid-single digit organic revenue growth and an adjusted EBITDA margin of 13%-14% for FY 2025, with an improvement of 100 basis points per year in the following two years.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 11:34 am

TECH

Bio-Techne has been granted European IVDR certification for its diagnostic test designed to monitor Chronic Myeloid Leukemia. This certification allows the company to market and sell the test in European markets, potentially expanding its customer base and increasing revenue from its diagnostic products segment.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 11:07 am

NKE

Nike's shares dropped in premarket trading after the company announced expectations for revenue to decrease in the first half of fiscal 2025 by low single digits. Despite this, the CFO remains optimistic, projecting a 1% revenue growth for the full year and a slight increase in Q4 revenue.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 10:59 am